Obesity is associated with an increased risk of fatal prostate cancer. We aimed to elucidate the importance and relevant timing of obesity and weight change for prostate cancer progression. We identified 5,158 men diagnosed with localized prostate cancer (clinical stage T1/T2) from 1986 to 2012 in the Health Professionals Follow-up Study. Men were followed for biochemical recurrence and lethal prostate cancer (development of distant metastasis or prostate cancer-specific mortality) until 2012. Cox regression estimated hazard ratios (HRs) for body mass index (BMI) at age 21, BMI at diagnosis, "long-term" weight change from age 21 to diagnosis and "short-term" weight change over spans of 4 and 8 years preceding diagnosis. Because weight, weight change and mortality are strongly associated with smoking, we repeated analyses among never smokers only (N 5 2,559). Among all patients, neither weight change nor BMI (at age 21 or at diagnosis) was associated with lethal prostate cancer. Among never smokers, long-term weight gain was associated with an increased risk of lethal disease (HR for gaining >30 pounds vs. stable weight [610 pounds] 1.59, 95% CI, 1.01-2.50, p-trend 5 0.06). Associations between weight change, BMI and lethal prostate cancer were stronger for men with BMI 25 at age 21 compared to those with BMI < 25. Weight change and obesity were not associated with an increased risk of biochemical recurrence. Our findings among never smoker men diagnosed with localized prostate cancer suggest a positive association between long-term weight gain and risk of lethal prostate cancer. Metabolic changes associated with weight gain may promote prostate cancer progression.
Obesity is a significant global health problem, and two-thirds of U.S. men are overweight or obese. 1 Both obesity and weight gain in adulthood have been linked with a higher risk of advanced and fatal prostate cancer as well as prostate cancer recurrence and survival. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Because obesity is common and potentially modifiable, more data on the relevant timing of obesity and the influence of weight change on risk are needed.
Findings for "long-term" adult weight change, from age 18-21 to midlife, and prostate cancer outcomes have been mixed. Several studies among men without cancer at baseline suggest that weight gain over this time frame may increase advanced and fatal prostate cancer risk. [4] [5] [6] However, others have reported no association. 15 ,16 "Short-term" weight gain around the time of prostate cancer diagnosis or treatment has been associated with an increased risk of prostate cancerspecific mortality 17 and biochemical recurrence 18, 19 in studies among men with prostate cancer. A meta-analysis 3 found obesity at the time of diagnosis or primary treatment to be associated with an increased risk of prostate cancer-specific mortality and biochemical recurrence. However, there was significant heterogeneity between studies, suggesting that associations between obesity and prostate cancer outcomes may vary by patient characteristics, treatment, timing of BMI measurement or length of follow-up. Thus, a better understanding of the patterns and timing of weight gain and obesity is needed. We examined the association between obesity, weight change and risk of lethal prostate cancer and biochemical recurrence among men diagnosed with localized prostate cancer in a prospective cohort study with multiple measures of weight over time and several decades of follow-up. Because the etiologically relevant time windows for obesity and weight change remain unclear, we examined these associations over various time windows: (1) "long-term" weight change from age 21 to time of prostate cancer diagnosis, (2) "short-term" weight change over spans of 4 years and 8 years preceding prostate cancer diagnosis, (3) BMI at age 21 and (4) BMI at diagnosis. Further, because smoking is strongly associated with BMI, weight change and mortality, we also examined these associations after restricting to never smokers only. We hypothesize that weight gain and obesity are associated with an increased risk of lethal prostate cancer and biochemical recurrence.
Material and Methods

Study population
The Health Professionals Follow-up Study (HPFS) is an ongoing prospective cohort study of 51,529 U.S. male health professionals aged 40-75 years at enrollment in 1986. Patients reported detailed information on demographics, medical diagnoses, height, weight, smoking and physical activity at baseline and every 2 years thereafter (average questionnaire response rate >90%). Dietary data were collected via food frequency questionnaire at baseline and every 4 years thereafter.
The primary study population includes 5,158 men who were diagnosed with localized prostate cancer (clinical stage T1/T2) from 1986 to 2012 and who had data on weight at age 21 and at the time of prostate cancer diagnosis. Because weight, weight change and mortality are strongly associated with smoking, 20, 21 we also conducted analyses restricted to never smokers (N 5 2,559). We excluded men with weight <100 pounds (45.4 kg) at age 21 or at diagnosis (N 5 2), BMI <15 or >45 at age 21 or at diagnosis (N 5 10), weight change >40 pounds (18.1 kg) in the 4 years preceding diagnosis (N 5 16) and baseline diseases potentially associated with weight status (cancer, ulcerative colitis, liver failure, renal failure) (N 5 20). The HPFS study was approved by the institutional review board of the Harvard T.H. Chan School of Public Health.
Exposure assessment
Men reported their current height and weight on the baseline 1986 questionnaire and their current weight every two years thereafter. Weight at age 21 was reported on the baseline questionnaire. A validation study in HPFS showed that selfreported and technician-measured weights were highly correlated (Pearson r 5 0.97). 22 Recalled weight during early adulthood among men has also been shown to be accurate (Pearson r 5 0.80) in other studies. 23 We assessed long-term weight change from age 21 to time of prostate cancer diagnosis (weight reported in the 2-year questionnaire cycle immediately preceding prostate cancer diagnosis). Men were classified as having lost >10 pounds (4.5 kg), lost 10 to gained 10 pounds (stable weight), gained 10.1-20 pounds (4.6-9.1 kg), gained 20.1-30 pounds (9.2-13.6 kg), or gained >30 pounds over this time frame. We also assessed the rate of long-term weight change (pounds/ year) from age 21 to diagnosis.
We assessed short-term weight change over 4 years and 8 years preceding diagnosis. This was calculated as the weight reported in the questionnaire cycle immediately preceding diagnosis minus the weight reported 4 or 8 years prior, depending on the exposure being modeled. Men were classified as having lost >5 pounds (2.3 kg), lost 5 to gained 5 pounds (stable weight), or gained >5 pounds over these time frames. Slightly fewer participants contributed to these analyses since weight change over the 4 and 8 years preceding diagnosis could only be calculated for those diagnosed after 1990 and 1994, respectively.
BMI Our primary outcome was lethal prostate cancer, defined as diagnosis of distant metastases or death due to prostate cancer. The occurrence of metastases (including site and date of detection) was determined by review of medical records, physician and patient questionnaires and death certificates. Study physicians confirmed cause of death through review of medical records and death certificates. A death was attributed to prostate cancer if prostate cancer metastases were present and no more-plausible cause of death was mentioned. Follow-up for mortality in this cohort is >98%.
Our secondary outcome was biochemical recurrence, as reported by participants, the treating physician, or abstracted from medical records. Recurrence was defined based on the primary treatment: for radical prostatectomy, PSA >0.2 ng/ mL after treatment for at least two consecutive measures 24 ; for external beam radiation, an increase of 2 ng/mL higher than the lowest recorded PSA 25 ; and for brachytherapy, hormones or other treatments, an increase of 1 ng/mL higher than the lowest recorded PSA for at least two consecutive measures. 26 The date of first increase in PSA was considered the date of recurrence. Analysis of PSA recurrence was restricted to men who had completed at least one prostate cancer-specific follow-up questionnaire (N 5 4,482), as PSA status after initial treatment is unknown among men who did not complete a follow-up questionnaire.
Statistical analysis
Descriptive analyses were performed to characterize the study population and examine differences across categories of weight change, with means and standard deviations presented for continuous variables and counts and percentages for categorical variables. Cox proportional hazards models were used to estimate age-adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) for the outcomes of lethal prostate cancer, biochemical recurrence and total mortality. Follow-up time for each participant accrued from the date of prostate cancer diagnosis to the earliest of the following events: development of lethal prostate cancer or PSA recurrence (depending on the endpoint for the analysis), death from other causes, or end of follow-up (January 1, 2012).
We adjusted for age at diagnosis (years, continuous) and baseline weight (defined as weight at age 21 for the analysis of long-term weight change or at 4 or 8 years prior to diagnosis for the analyses of short-term weight change) in all analyses. Because weight and weight change are correlated, adjusting for baseline weight allowed us to isolate the independent association of weight change and prostate cancer outcomes. In multivariable models, we additionally adjusted for race (Caucasian, African American, Asian, other), family history of prostate cancer (yes/no), height (continuous), smoking status at diagnosis (never smokers, past: quit >10 years ago, past: quit 10 years ago, current smokers), diabetes at diagnosis (yes/no), heart/lung disease by time of diagnosis (yes/no for the presence of any of the following conditions: myocardial infarction, coronary artery bypass graft, cerebral vascular accident, pulmonary embolism), intakes of tomato sauce, coffee, alpha-linolenic acid, calcium, and energy (all continuous) and physical activity at diagnosis (MET-hours/week, continuous). In additional models, we further adjusted for clinical stage (T1, T2), Gleason grade (<7, 7, >7; determined from prostatectomy pathology report, if applicable/available, or from biopsy pathology report otherwise), PSA at diagnosis (<4, 4-<10, 10 ng/mL) and primary treatment (radiation therapy, radical prostatectomy, hormones, no initial treatment/watchful waiting, other). Missing data for categorical covariates were assigned a missing indicator, and median imputation was performed for participants missing data for continuous covariates. To test for trend across categories of weight change or BMI, we used the Wald test for a continuous variable using the median value for each category.
Because weight, weight change and overall mortality are strongly associated with smoking, we also conducted analyses among never smokers only (N 5 2,559) to prevent potential confounding by smoking. Because diabetes is associated with weight and prostate cancer outcomes, we also repeated the analyses among men without diabetes at the time of diagnosis (N 5 4,889). We were interested in examining the influence of weight change among men whose weight was not changing due to diabetes, because different metabolic processes may be at play among diabetics.
We further conducted pre-specified stratified analyses to evaluate whether the association between weight change, BMI and lethal prostate cancer varied by primary treatment type (radical prostatectomy versus radiation therapy) or BMI at age 21 (<25 vs. 25 kg/m 2 ). Tests for interaction were performed using likelihood ratio tests comparing models with and without an interaction term between the exposure of interest and the possible effect modifier. Finally, we conducted sensitivity analyses (1) excluding men with a BMI 17 at age 21 or at time of diagnosis and (2) excluding the first four years after diagnosis for all participants.
Analyses were conducted using SAS version 9.3 (SAS institute Inc., Cary, NC). All statistical tests were two-sided, and p-values <0.05 were considered statistically significant.
Results
Among 5,158 men diagnosed with clinically localized prostate cancer (cT1 or T2), there were 371 lethal events and 804 biochemical recurrence events over the study period. The mean survival time from diagnosis was 9.5 years for the outcome of lethal prostate cancer and 8.5 years for biochemical recurrence.
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Dickerman et al. Demographic, lifestyle and clinical characteristics of the study population are presented in Table 1 by category of long-term weight change. The distribution of long-term weight change was as follows: 5% lost >10 pounds, 28% had stable weight (610 pounds), 20% gained 10.1-20 pounds, 18% gained 20.1-30 pounds and 29% gained >30 pounds. Those who gained >30 pounds had a lower BMI at age 21 and were less likely to be physically active or current smokers at the time of diagnosis compared to those in the other weight change categories. Similar tables by category of 4-year and 8-year weight change are presented as Supporting Information Tables 1 and 2 . Men who lost weight in the 8 years prior to diagnosis were more likely to have heart/lung disease at diagnosis (23% vs. 15% in the stable weight group and 16% in the weight gain group). Other characteristics were similar across 4-and 8-year weight change groups.
Among all patients, long-term weight gain from age 21 to the time of diagnosis was not associated with an increased risk of lethal prostate cancer (Table 2 ). However, in the subset of men who were never-smokers, higher long-term weight gain was associated with an increased risk of lethal disease. In this subset of 2,559 men, those who gained 20.1-30 pounds had a 1.64-fold higher risk (95% CI, 1.01-2.67) and those who gained >30 pounds had a 1.59-fold higher risk (95% CI, 1.01-2.50) of lethal cancer compared to those with stable weight in fully adjusted models (p-trend 5 0.06). An increase in rate of weight gain of one pound/year for the period from age 21 to diagnosis was associated with an increased risk among never-smokers only (HR 1.47, 95% CI, 1.01-2.14). In contrast, short-term weight gain was not associated with risk of lethal prostate cancer in the overall study population or among never smokers (Table 2) .
Neither BMI at age 21 nor at diagnosis was significantly associated with risk of lethal prostate cancer (Table 3 ). BMI at age 21 was suggestively, but not significantly, inversely associated with risk of lethal prostate cancer, whereas BMI at diagnosis was suggestively, but not significantly, positively associated with lethal prostate cancer risk among never smokers.
As expected, long-term weight gain was positively associated with total mortality, while short-term weight change was not (data not shown). BMI at age 21 and at diagnosis was positively associated with total mortality (data not shown).
Biochemical recurrence
Neither weight change nor obesity was associated with an increased risk of biochemical recurrence among the subset of men with data on PSA levels following initial treatment (Supporting Information Tables 3-5 ). In fact, we detected a significant inverse trend for risk of biochemical recurrence with increasing categories of 8-year weight change (HR for gaining >5 pounds vs. stable weight [65 pounds] 0.68, 95% CI, 0.56-0.83, p-trend 5 0.02). However, among this subset of men with biochemical recurrence data, 8-year weight change 
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Dickerman et al. was not associated with lethal cancer risk (Supporting Information Table 4 ).
Subgroup analyses
The association between long-term and short-term weight change and lethal prostate cancer was stronger for men who were overweight or obese at age 21 compared to men who had a healthy BMI at age 21 ( No significant interactions between primary treatment and weight change were found (data not shown); however, the associations for long-term weight change appeared to vary by primary treatment. For men receiving prostatectomy, there was a suggestion of an increased risk of lethal cancer among those who gained >30 pounds from age 21 to diagnosis compared to those with stable weight (610 pounds) (HR 1.81, 95% CI, 1.04-3.15; p-trend 5 0.19). In contrast, among men receiving radiation as their primary treatment, long-term weight gain was not associated with lethal prostate cancer. 
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Sensitivity analyses
Results for lethal prostate cancer among the subset of men in the biochemical recurrence analysis were similar to the results for the total study population (Supporting Information  Tables 3-5) . Estimates were similar, but attenuated, when our smoking restriction was expanded to include distant previous smokers (quit >10 years prior to diagnosis) in addition to never-smokers (data not shown). Results were similar when we excluded men with diabetes at the time of diagnosis and when we excluded men with very low BMI (<17 kg/m 2 ) at age 21 or the time of diagnosis (data not shown).
Estimates were stronger when we excluded the first four years after diagnosis for all participants (Table 5) . In this analysis, those who gained >30 pounds from age 21 to diagnosis had a 1.45-fold higher risk of lethal cancer compared to those with stable weight (610 pounds) (95% CI, 1.02-2.06, p-trend 5 0.06) in fully adjusted models. This Note: All models also adjusted for weight at age 21, weight 4 years prior to diagnosis, or weight 8 years prior to diagnosis, respectively. 1 Models adjusted for the following covariates: age at diagnosis, race, family history of prostate cancer, height, smoking status at diagnosis, diabetes at diagnosis, heart/lung disease by time of diagnosis (MI, CABG, CVA, PE), physical activity, energy intake, tomato sauce intake, coffee intake, alpha-linolenic acid, calcium intake, clinical stage, grade, PSA at diagnosis and primary treatment.
association was stronger among never smokers (HR 2.31, 95% CI, 1.35-3.98, p-trend 5 0.001).
Discussion
In this prospective cohort study of men with localized prostate cancer, neither long-term nor short-term weight gain was associated with development of lethal disease. In addition, neither BMI at diagnosis nor at age 21 was significantly associated with lethal prostate cancer risk. However, longterm weight gain was associated with an increased risk of lethal prostate cancer among never smokers-a group in which residual confounding by smoking is not a concernand among men who were overweight or obese at age 21. Weight change and obesity were not associated with an increased risk of biochemical recurrence. In fact, we detected an inverse association for 8-year weight change. A recent study of men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial examined BMI trajectories over adulthood and risk of fatal prostate cancer, reporting an increased risk among men who had a healthy BMI (HR 1.95, 95% CI, 1.21-3.12) or overweight BMI (HR 2.65, 95% CI, 1.35-5.18) at age 20 and developed obesity by baseline compared to men with a stable healthy BMI. 27 Several cohort studies have assessed long-term weight gain and incidence of advanced or fatal prostate cancer. Four studies found positive associations, 4-7 while two found no association. 15, 16 Only one study has examined short-term weight gain around the time of prostate cancer diagnosis and risk of prostate cancer-specific mortality, finding a nearly twofold higher risk of prostate cancer-specific mortality for weight gain of >5% compared to stable weight in the 5-10 years after diagnosis of localized prostate cancer. 17 In contrast, we found no association between weight gain in the 4-8 years prior to diagnosis and prostate cancer survival.
Several studies have examined both long-term and shortterm weight gain and risk of biochemical recurrence among patients treated with prostatectomy. One study reported a positive association between weight gain from age 25 to diagnosis and risk of biochemical recurrence, although only an unadjusted analysis was reported. 10 Two studies reported that Note: All models also adjusted for weight at age 21. Models restricted to never-smokers did not adjust for smoking status at diagnosis.
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short-term weight gain-in the year before surgery 19 or from 5 years before to 1 year after surgery 18 -was associated with an increased risk of biochemical recurrence. In contrast, we found an inverse association between 8-year weight change and biochemical recurrence in our study population. This finding may be due to hemodilution among obese men, such that PSA concentrations may be lower due to a greater blood volume, 28 or to chance. A meta-analysis of prospective studies reported positive associations between BMI, prostate cancer-specific mortality and biochemical recurrence. 3 In six reviewed survival studies, a 5 kg/m 2 increase in BMI was associated with a 20% higher risk of prostate cancer-specific mortality (RR 1.20, 95% CI, 0.99-1.46). We found no association between BMI at diagnosis and risk of lethal cancer in our overall study population, but a 15% increased risk for every 5 kg/m 2 increase in BMI at diagnosis among never smokers. The meta-analysis also reviewed 16 studies of treated prostate cancer patients, reporting an RR of 1.21 for biochemical recurrence for every 5 kg/m 2 increase in BMI (95% CI, 1.11-1.31). In contrast, we found no association between obesity and biochemical recurrence.
Our analysis of biochemical recurrence was restricted to men completing at least one prostate cancer-specific followup questionnaire, which began in 2000. This limits our study population and likely results in some misclassification of the outcome, particularly compared to clinic-based cohorts with more complete ascertainment of post-treatment PSA levels over time. On the other hand, biochemical recurrence is a fairly weak proxy for fatal disease, as only about 10-30% of men experiencing a recurrence go on to develop metastases or die of prostate cancer. 29 Just as risk factors have been shown to differ for aggressive versus non-aggressive prostate cancers, 30 it is plausible that risk factors may be differently associated with biochemical recurrence and disease-specific mortality among men with prostate cancer.
Because smoking is strongly associated with weight, weight change and prostate cancer-specific and total mortality, we considered it important to repeat all of our analyses among never-smokers only. 20, 21 We found associations between weight gain, obesity and prostate cancer outcomes to be strongest in this subset of men, suggesting residual confounding by smoking in analyses of the full study population. A recent investigation examining body shape trajectory over the lifespan and cancer risk similarly found that trajectories were more strongly associated with cancer among never smokers (p interaction 50.18 for advanced/lethal prostate cancer). 31 Interestingly, estimates for long-term weight change were also stronger in sensitivity analyses excluding the first four years of follow-up. These estimates may be relevant to our study question if reverse causation is at play or if the clinical stage was more likely misclassified for those who died within four years of localized prostate cancer diagnosis. This finding, coupled with our findings among never smoker men, suggests that weight gain may play an important role in the development of tumors more likely to progress.
Our subgroup analyses suggest that men who were overweight or obese at age 21 may be more susceptible to the influence of weight gain on prostate cancer progression. It is possible that weight change has a more immediate metabolic effect among overweight and obese men at that age, compared to men with a healthy BMI. It does not appear that this association is due solely to BMI status itself at age 21 or at diagnosis, as these were not themselves associated with survival. In fact, the association for BMI at age 21 was suggestively inverse among never smokers, which is in line with a recent report from this cohort that found an inverse association between BMI at age 21 and risk of incident fatal or advanced disease even after adjusting for later adult BMI. 32 Our findings therefore suggest that the weight gain itself may play a role in the increased risk of lethal prostate cancer that we observed among men with a higher BMI at age 21. However, we are unable to rule out the possibility of residual confounding by smoking, since we did not have the power to conduct our interaction analyses among never smokers only. Further investigation is needed to explore this potential interaction.
There is biologic rationale that obesity and weight gain may influence lethal prostate cancer risk through metabolic, hormonal and inflammatory pathways. Obese men tend to have higher levels of insulin, bioavailable insulin-like growth factor-1 (IGF-1) and lower levels of androgens and adiponectin. 14, 33 Evidence suggests that high insulin may increase the risk of prostate cancer progression.
14 Prolonged hyperinsulinemia decreases the production of IGF binding protein, resulting in higher levels of bioavailable IGF-1.
14 IGF-1 has been shown to promote proliferation and inhibit apoptosis in both normal prostate and tumor cells in vitro, 34 and high circulating IGF-1 levels have been associated with an increased risk of prostate cancer in this cohort and others. [35] [36] [37] However, an analysis of data from seven cohorts found no association between prediagnostic IGF-1 and survival among prostate cancer patients. 38 Obesity is also associated with altered levels of adipokines (e.g., increased leptin, decreased adiponectin), which have been associated with tumor development. 39 Of importance to tumor biology, adiponectin promotes apoptosis and inhibits proliferation and angiogenesis. 39 Higher pre-diagnostic adiponectin concentrations have been associated with a lower risk of developing high-grade or lethal cancer. 40 In addition, excess adiposity among men is associated with decreased levels of circulating testosterone, 41 which may facilitate the growth of poorly differentiated, aggressive prostate tumors. 42 Finally, obesity is associated with a low-grade chronic inflammatory state, and inflammation is thought to play an important role in prostate cancer progression. 43 The biologic influence of weight change is complex, and further research is needed to explore how its effects vary across the life course and how it affects various stages of prostate carcinogenesis. Our finding that long-term, but not short-term, weight gain was associated with lethal prostate cancer among never smokers suggests that weight gain may have an early influence on prostatic carcinogenesis.
This study benefits from a large sample size, long followup and use of lethal prostate cancer as the primary outcome. Importantly, we conducted analyses among never smokers to eliminate any confounding by this factor that is strongly associated with weight, weight change and mortality. Indeed, we found that associations were stronger when analyses were restricted to never smokers. In addition, we focused on weight change as a primary exposure of interest-a timeintegrated measure that, during adulthood, predominately captures changes in adiposity. This is in contrast to BMI, which reflects both fat mass and fat free mass, often at a single time point.
Several limitations should be noted. It is difficult to disentangle the influence of obesity and weight gain, since most significant weight gain is associated with becoming obese. Further, it has been hypothesized that prostate cancer may be difficult to detect in obese men due to lower PSA values resulting from hemodilution and decreased biopsy accuracy due to larger-sized prostates. 44, 45 Delayed detection of prostate cancer in obese men might translate to a more advanced disease at diagnosis and worse prognosis, which might partially explain observations of a higher risk of fatal prostate cancer for men with higher weight gain. However, associations persisted with adjustment for stage, grade, PSA at diagnosis and primary treatment. We relied on self-reported anthropometric measures and thus exposure misclassification cannot be entirely ruled out. However, a prior validation study in HPFS showed that self-reported and technicianmeasured weights were highly correlated (r 5 0.97). 21 In addition, current weight and recalled weight at age 21 (reported in 1986) were both collected prior to the occurrence of prostate cancer outcomes and any misclassification is likely non-differential. Our cohort consisted primarily of Caucasian male health professionals, which may limit the generalizability of our findings. Finally, given the observational nature of this study, there remains a potential for unmeasured confounding. However, we did attempt to control for a wide array of potential confounders.
Conclusion
In conclusion, we found a positive association between longterm weight gain and risk of lethal prostate cancer among never smoker men, but not among all men diagnosed with clinically localized prostate cancer. In contrast, BMI at age 21 and at the time of diagnosis were not associated with risk of lethal disease. These findings suggest that metabolic changes associated with weight gain may promote the development of tumors more likely to progress. Further, such changes occurring decades before diagnosis may be most etiologically relevant for the development of lethal prostate cancer. Future studies are needed to further explore the timing and rate of weight change as it relates to clinically relevant prostate cancer, as well as potential underlying mechanisms.
